Gilead Sciences Says Study of GS-6207 Showed HIV Capsid Inhibition Can Lead Viral Load Declines

By Stephen Nakrosis

Gilead Sciences, Inc. (GILD) said Monday data from a Phase 1b study of its GS-6207 demonstrated "the first proof of concept that HIV capsid inhibition can lead to significant declines in viral load in vivo."

Gilead said GS-6207 is "an investigational long-acting antiretroviral agent," which was recently given a breakthrough therapy designation by the U.S. Food and Drug Administration. GS-6207 is a "potential therapy for heavily treatment-experienced people living with multi-drug resistant HIV," the company said.

Gilead said GS-6207 acts to interrupt "the activity of HIV capsid, a protein that surrounds and protects the virus' genetic material and essential enzymes." The company said it can potentially keep the virus from becoming infectious and accessing uninfected cells.

Gilead said the treatment's safety and efficacy have yet to be established.

Data from the study was presented at the International AIDS Society Conference on HIV Science in Mexico City.

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

July 22, 2019 11:36 ET (15:36 GMT)

Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024